These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29934047)

  • 1. Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients.
    Southworth T; Kaur M; Hodgson L; Facchinetti F; Villetti G; Civelli M; Singh D
    Cytokine; 2019 Jan; 113():68-73. PubMed ID: 29934047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
    Gianello V; Salvi V; Parola C; Moretto N; Facchinetti F; Civelli M; Villetti G; Bosisio D; Sozzani S
    Biochem Pharmacol; 2019 May; 163():371-380. PubMed ID: 30851246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
    Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
    J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
    Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
    Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
    Govoni M; Bassi M; Vezzoli S; Lucci G; Emirova A; Nandeuil MA; Petruzzelli S; Jellema GL; Afolabi EK; Colgan B; Leaker B; Kornmann O; Beeh KM; Watz H; Singh D
    Respir Res; 2020 Mar; 21(1):72. PubMed ID: 32197620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
    Singh D; Leaker B; Boyce M; Nandeuil MA; Collarini S; Mariotti F; Santoro D; Barnes PJ
    Pulm Pharmacol Ther; 2016 Oct; 40():1-6. PubMed ID: 27373438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
    Villetti G; Carnini C; Battipaglia L; Preynat L; Bolzoni PT; Bassani F; Caruso P; Bergamaschi M; Pisano AR; Puviani V; Stellari FF; Cenacchi V; Volta R; Bertacche V; Mileo V; Bagnacani V; Moretti E; Puccini P; Catinella S; Facchinetti F; Sala A; Civelli M
    J Pharmacol Exp Ther; 2015 Mar; 352(3):568-78. PubMed ID: 25576073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of
    Fontana E; Cenacchi V; Pivetti F; Pignatti A; Pazzi T; Bondanza L; Pazzi M
    J Labelled Comp Radiopharm; 2017 Oct; 60(12):577-585. PubMed ID: 28763109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.
    Yang YL; Hsu HT; Wang KH; Han CY; Chen CM; Chen CM; Ko WC
    J Biomed Sci; 2011 Nov; 18(1):84. PubMed ID: 22074248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
    Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE
    Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
    Singh D; Beeh KM; Colgan B; Kornmann O; Leaker B; Watz H; Lucci G; Geraci S; Emirova A; Govoni M; Nandeuil MA
    Respir Res; 2019 Aug; 20(1):180. PubMed ID: 31399091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
    Demizu S; Asaka N; Kawahara H; Sasaki E
    Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PDE4 inhibitor CHF6001 affects keratinocyte proliferation via cellular redox pathways.
    Woodby B; Sticozzi C; Pambianchi E; Villetti G; Civelli M; Valacchi G; Facchinetti F
    Arch Biochem Biophys; 2020 May; 685():108355. PubMed ID: 32268137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.
    Schioppa T; Nguyen HO; Salvi V; Maugeri N; Facchinetti F; Villetti G; Civelli M; Gaudenzi C; Passari M; Sozio F; Barbazza I; Tamassia N; Cassatella MA; Del Prete A; Bosisio D; Tiberio L
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokines.
    Edwards MR; Facchinetti F; Civelli M; Villetti G; Johnston SL
    Pharmacol Res Perspect; 2016 Feb; 4(1):e00202. PubMed ID: 26977295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.
    Singh D; Emirova A; Francisco C; Santoro D; Govoni M; Nandeuil MA
    Respir Res; 2020 Sep; 21(1):246. PubMed ID: 32962709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siraitia grosvenorii residual extract attenuates ovalbumin-induced lung inflammation by down-regulating IL-4, IL-5, IL-13, IL-17, and MUC5AC expression in mice.
    Sung YY; Kim SH; Yuk HJ; Yang WK; Lee YM; Son E; Kim DS
    Phytomedicine; 2019 Aug; 61():152835. PubMed ID: 31035047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory effects of ethanolic extract from Lagerstroemia indica on airway inflammation in mice.
    Yang EJ; Lee JS; Song BB; Yun CY; Kim DH; Kim IS
    J Ethnopharmacol; 2011 Jul; 136(3):422-7. PubMed ID: 20600763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BuShenYiQi Formula strengthens Th1 response and suppresses Th2-Th17 responses in RSV-induced asthma exacerbated mice.
    Wang J; Wu J; Kong L; Nurahmat M; Chen M; Luo Q; Li B; Wu X; Dong J
    J Ethnopharmacol; 2014 May; 154(1):131-47. PubMed ID: 24704667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.